Haloperidol dose and blood level variability : toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting
Haloperidol levels in blood were measured monthly in 43 refractory chronic schizophrenic patients referred to a locked skilled nursing facility for long-term treatment. Gross toxic side effects (seizures, catatonia, confusion) and Neuroleptic Induced Deficit Syndrome in conjunction with blood levels...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical psychopharmacology 1995-10, Vol.15 (5), p.334-340 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 5 |
| container_start_page | 334 |
| container_title | Journal of clinical psychopharmacology |
| container_volume | 15 |
| creator | DARBY, J. K PASTA, D. J DABIRI, L CLARK, L MOSBACHER, D |
| description | Haloperidol levels in blood were measured monthly in 43 refractory chronic schizophrenic patients referred to a locked skilled nursing facility for long-term treatment. Gross toxic side effects (seizures, catatonia, confusion) and Neuroleptic Induced Deficit Syndrome in conjunction with blood levels over 30 ng/ml were identified in 13 of our 43 patients. Blood level reductions contributed to a reduction of side effects and clinical improvement and led to the expedited discharge of 6 of these 13 patients of the toxic subgroup. Considerable blood level variation was evident in single samples, and four levels appeared necessary to develop confidence for accuracy. Significant dose to blood level interindividual variability was identified, thereby bringing into question fixed-dose approaches to patients. The results strongly suggest the utility of haloperidol blood levels in the clinical setting. |
| doi_str_mv | 10.1097/00004714-199510000-00005 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00004714_199510000_00005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8830064</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-4464591521b3796d63f3610ce8c198175e77c2478e27928e8c4ddfd7c5ac3e363</originalsourceid><addsrcrecordid>eNpNkM1qGzEUhUVJcZy0jxDQottp9DsadVdCEgcC2bTQ3SBLdxoFWRok2TRv1MfsTP2D70L36pz7CXQQwpR8pUSrWzKVUFQ0VGtJ51szH_IDWlLJeaMo-3WBloQp2hAl9CW6KuWNECoUkwu06DpOSCuW6O_KhDRC9i4F7FIBbKLD65CSwwF2EPDOZG_WPvj6jr_hmv54O4_zmo91IqPzO--2Jhy1bM60c9xHXF8BxxQzlDFFBxmPpnqI9ejZ4KO3EzdmY6u3gAvU6uPvT-jjYEKBz4d-jX4-3P-4WzXPL49Pd9-fG8s6URshWiE1lYyuudKta_nAW0osdJbqjioJSlkmVAdMadZNsnBucMpKYznwll-jbv-uzamUDEM_Zr8x-b2npJ-z74_Z96fs_0tyQm_26Lhdb8CdwEPYk__l4JsyfXHIJlpfTmu81Yq3jP8DE3WQKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Haloperidol dose and blood level variability : toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>DARBY, J. K ; PASTA, D. J ; DABIRI, L ; CLARK, L ; MOSBACHER, D</creator><creatorcontrib>DARBY, J. K ; PASTA, D. J ; DABIRI, L ; CLARK, L ; MOSBACHER, D</creatorcontrib><description>Haloperidol levels in blood were measured monthly in 43 refractory chronic schizophrenic patients referred to a locked skilled nursing facility for long-term treatment. Gross toxic side effects (seizures, catatonia, confusion) and Neuroleptic Induced Deficit Syndrome in conjunction with blood levels over 30 ng/ml were identified in 13 of our 43 patients. Blood level reductions contributed to a reduction of side effects and clinical improvement and led to the expedited discharge of 6 of these 13 patients of the toxic subgroup. Considerable blood level variation was evident in single samples, and four levels appeared necessary to develop confidence for accuracy. Significant dose to blood level interindividual variability was identified, thereby bringing into question fixed-dose approaches to patients. The results strongly suggest the utility of haloperidol blood levels in the clinical setting.</description><identifier>ISSN: 0271-0749</identifier><identifier>EISSN: 1533-712X</identifier><identifier>DOI: 10.1097/00004714-199510000-00005</identifier><identifier>PMID: 8830064</identifier><identifier>CODEN: JCPYDR</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Administration, Oral ; Adult ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - pharmacokinetics ; Biological and medical sciences ; Biological Availability ; Chronic Disease ; Dose-Response Relationship, Drug ; Female ; Haloperidol - administration & dosage ; Haloperidol - adverse effects ; Haloperidol - pharmacokinetics ; Humans ; Long-Term Care ; Male ; Medical sciences ; Metabolic Clearance Rate - physiology ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Psychoses, Substance-Induced - blood ; Psychoses, Substance-Induced - diagnosis ; Psychoses, Substance-Induced - psychology ; Schizophrenia - blood ; Schizophrenia - drug therapy ; Schizophrenic Psychology</subject><ispartof>Journal of clinical psychopharmacology, 1995-10, Vol.15 (5), p.334-340</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c284t-4464591521b3796d63f3610ce8c198175e77c2478e27928e8c4ddfd7c5ac3e363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3697362$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8830064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DARBY, J. K</creatorcontrib><creatorcontrib>PASTA, D. J</creatorcontrib><creatorcontrib>DABIRI, L</creatorcontrib><creatorcontrib>CLARK, L</creatorcontrib><creatorcontrib>MOSBACHER, D</creatorcontrib><title>Haloperidol dose and blood level variability : toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>Haloperidol levels in blood were measured monthly in 43 refractory chronic schizophrenic patients referred to a locked skilled nursing facility for long-term treatment. Gross toxic side effects (seizures, catatonia, confusion) and Neuroleptic Induced Deficit Syndrome in conjunction with blood levels over 30 ng/ml were identified in 13 of our 43 patients. Blood level reductions contributed to a reduction of side effects and clinical improvement and led to the expedited discharge of 6 of these 13 patients of the toxic subgroup. Considerable blood level variation was evident in single samples, and four levels appeared necessary to develop confidence for accuracy. Significant dose to blood level interindividual variability was identified, thereby bringing into question fixed-dose approaches to patients. The results strongly suggest the utility of haloperidol blood levels in the clinical setting.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Chronic Disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Haloperidol - administration & dosage</subject><subject>Haloperidol - adverse effects</subject><subject>Haloperidol - pharmacokinetics</subject><subject>Humans</subject><subject>Long-Term Care</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate - physiology</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses, Substance-Induced - blood</subject><subject>Psychoses, Substance-Induced - diagnosis</subject><subject>Psychoses, Substance-Induced - psychology</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><issn>0271-0749</issn><issn>1533-712X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM1qGzEUhUVJcZy0jxDQottp9DsadVdCEgcC2bTQ3SBLdxoFWRok2TRv1MfsTP2D70L36pz7CXQQwpR8pUSrWzKVUFQ0VGtJ51szH_IDWlLJeaMo-3WBloQp2hAl9CW6KuWNECoUkwu06DpOSCuW6O_KhDRC9i4F7FIBbKLD65CSwwF2EPDOZG_WPvj6jr_hmv54O4_zmo91IqPzO--2Jhy1bM60c9xHXF8BxxQzlDFFBxmPpnqI9ejZ4KO3EzdmY6u3gAvU6uPvT-jjYEKBz4d-jX4-3P-4WzXPL49Pd9-fG8s6URshWiE1lYyuudKta_nAW0osdJbqjioJSlkmVAdMadZNsnBucMpKYznwll-jbv-uzamUDEM_Zr8x-b2npJ-z74_Z96fs_0tyQm_26Lhdb8CdwEPYk__l4JsyfXHIJlpfTmu81Yq3jP8DE3WQKA</recordid><startdate>19951001</startdate><enddate>19951001</enddate><creator>DARBY, J. K</creator><creator>PASTA, D. J</creator><creator>DABIRI, L</creator><creator>CLARK, L</creator><creator>MOSBACHER, D</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19951001</creationdate><title>Haloperidol dose and blood level variability : toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting</title><author>DARBY, J. K ; PASTA, D. J ; DABIRI, L ; CLARK, L ; MOSBACHER, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-4464591521b3796d63f3610ce8c198175e77c2478e27928e8c4ddfd7c5ac3e363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Chronic Disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Haloperidol - administration & dosage</topic><topic>Haloperidol - adverse effects</topic><topic>Haloperidol - pharmacokinetics</topic><topic>Humans</topic><topic>Long-Term Care</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate - physiology</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses, Substance-Induced - blood</topic><topic>Psychoses, Substance-Induced - diagnosis</topic><topic>Psychoses, Substance-Induced - psychology</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DARBY, J. K</creatorcontrib><creatorcontrib>PASTA, D. J</creatorcontrib><creatorcontrib>DABIRI, L</creatorcontrib><creatorcontrib>CLARK, L</creatorcontrib><creatorcontrib>MOSBACHER, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DARBY, J. K</au><au>PASTA, D. J</au><au>DABIRI, L</au><au>CLARK, L</au><au>MOSBACHER, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Haloperidol dose and blood level variability : toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>1995-10-01</date><risdate>1995</risdate><volume>15</volume><issue>5</issue><spage>334</spage><epage>340</epage><pages>334-340</pages><issn>0271-0749</issn><eissn>1533-712X</eissn><coden>JCPYDR</coden><abstract>Haloperidol levels in blood were measured monthly in 43 refractory chronic schizophrenic patients referred to a locked skilled nursing facility for long-term treatment. Gross toxic side effects (seizures, catatonia, confusion) and Neuroleptic Induced Deficit Syndrome in conjunction with blood levels over 30 ng/ml were identified in 13 of our 43 patients. Blood level reductions contributed to a reduction of side effects and clinical improvement and led to the expedited discharge of 6 of these 13 patients of the toxic subgroup. Considerable blood level variation was evident in single samples, and four levels appeared necessary to develop confidence for accuracy. Significant dose to blood level interindividual variability was identified, thereby bringing into question fixed-dose approaches to patients. The results strongly suggest the utility of haloperidol blood levels in the clinical setting.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>8830064</pmid><doi>10.1097/00004714-199510000-00005</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-0749 |
| ispartof | Journal of clinical psychopharmacology, 1995-10, Vol.15 (5), p.334-340 |
| issn | 0271-0749 1533-712X |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00004714_199510000_00005 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Administration, Oral Adult Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - pharmacokinetics Biological and medical sciences Biological Availability Chronic Disease Dose-Response Relationship, Drug Female Haloperidol - administration & dosage Haloperidol - adverse effects Haloperidol - pharmacokinetics Humans Long-Term Care Male Medical sciences Metabolic Clearance Rate - physiology Middle Aged Neuropharmacology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Psychoses, Substance-Induced - blood Psychoses, Substance-Induced - diagnosis Psychoses, Substance-Induced - psychology Schizophrenia - blood Schizophrenia - drug therapy Schizophrenic Psychology |
| title | Haloperidol dose and blood level variability : toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Haloperidol%20dose%20and%20blood%20level%20variability%20:%20toxicity%20and%20interindividual%20and%20intraindividual%20variability%20in%20the%20nonresponder%20patient%20in%20the%20clinical%20practice%20setting&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=DARBY,%20J.%20K&rft.date=1995-10-01&rft.volume=15&rft.issue=5&rft.spage=334&rft.epage=340&rft.pages=334-340&rft.issn=0271-0749&rft.eissn=1533-712X&rft.coden=JCPYDR&rft_id=info:doi/10.1097/00004714-199510000-00005&rft_dat=%3Cpubmed_cross%3E8830064%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8830064&rfr_iscdi=true |